News|Articles|March 16, 2021
- Pharmaceutical Technology-03-15-2021
- Volume 2021 eBook
- Issue 1
Managing the Risk of Nitrosamine Impurities
Author(s)Timothy Curran, J.P. Bercu
Advertisement
Collaborative industry efforts have shed light on ways industry standards can help pharma companies better understand the risks nitrosamines pose to the supply chain.
IQ Consortium working groups have engaged in ongoing efforts to evaluate risk models and guidance documents to help increase pharma industry knowledge about these impurities.
Article Details
Pharmaceutical Technology
eBook: Regulatory Sourcebook,
March 2021
Pages: 28–35
Citation
When referring to this article, please cite it as T. Curran and J.P. Bercu, "Managing the Risk of Nitrosamine Impurities," Pharmaceutical Technology Regulatory Sourcebook eBook (March 2021).
Articles in this issue
over 4 years ago
It Takes a Bio/Pharma Villageover 4 years ago
Collaborative Efforts Address Key Data Integrity Challengesover 4 years ago
Can FDA Reinvent Inspectionsover 4 years ago
FDA 2021 Guidance Agenda Sees Focus on Genericsover 4 years ago
A Real-World Approach to Evaluating Cleanroom Garmentsover 4 years ago
Resources, Guidelines, and Guidance Documents Directoryover 4 years ago
Regulatory and Standard Setting Organizations DirectoryNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Sustainability and Stability in Excipients
2
CPHI 2025 Awards Spotlight Breakthroughs in Pharmaceutical Manufacturing and API Development
3
Turning Real-World Data into Actionable Drug Development Insights With AI
4
The Bio/pharma Industry Navigates AI’s Impact on Workforce and Hiring
5
